Want to see KLRS full AI Analyst Report?
Kalaris Therapeutics (KLRS) Income Statement
Kalaris Therapeutics Income Statement
Last quarter (Q2 2026), Kalaris Therapeutics's total revenue was $0.00. In Q2, Kalaris Therapeutics's net income was $-11.52M. See Kalaris Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ -13.00K | $ 0.00 | $ 0.00 | $ 0.00 | $ -1.12M | |
| $ 46.14M | $ 55.26M | $ 13.46M | $ 14.01M | $ 168.70M | |
| Depreciation and Amortization | $ 13.00K | $ 0.00 | $ 0.00 | $ 0.00 | $ 1.12M |
| $ -41.98M | $ -58.77M | $ -14.01M | $ -15.25M | $ -169.84M | |
| $ -46.15M | $ -55.26M | $ -13.46M | $ -14.01M | $ -169.82M | |
| $ 2.71M | $ -3.51M | $ -1.24M | $ -1.48M | $ -1.14M | |
| $ -43.44M | $ -58.77M | $ -14.70M | $ -15.48M | $ -170.96M | |
| $ -43.44M | $ -58.77M | $ -14.70M | $ -15.48M | $ -171.96M | |
| Per Share Metrics | |||||
| Basic EPS | $ -2.85 | $ -11.73 | $ -42.09 | $ -50.62 | $ -63.00 |
| Diluted EPS | $ -2.85 | $ -11.73 | $ -42.09 | $ -50.62 | $ -63.00 |
| Weighted Average Shares Outstanding | 15.27M | 5.01M | 4.52M | 3.33M | 2.73M |
| Weighted Average Shares Outstanding (Diluted) | 15.27M | 5.01M | 4.52M | 3.33M | 2.73M |
Currency in USD
